Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease
An important hallmark of Alzheimer's disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incom...
Saved in:
Published in | Journal of neuroinflammation Vol. 17; no. 1; pp. 131 - 15 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
24.04.2020
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | An important hallmark of Alzheimer's disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incomplete understanding of its relevance for AD. The chemotactic G-protein coupled formyl peptide receptor (FPR), which is known to modulate Aβ1-42 uptake and signal transduction, might be one candidate molecule regulating glia function in AD. Here, we investigate whether the modulation of FPR exerts beneficial effects in an AD preclinical model.
To address this question, APP/PS1 double-transgenic AD mice were treated for 20 weeks with either the pro-inflammatory FPR agonist fMLF, the FPR1/2 antagonist Boc2 or the anti-inflammatory FPR2 agonist Ac2-26. Spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining, gene expression studies, and flow cytometry analyses were performed to study neuronal loss, gliosis, and Aß-load in the hippocampus and cortex, respectively.
FPR antagonism by Boc2-treatment significantly improved spatial memory performance, reduced neuronal pathology, induced the expression of homeostatic growth factors, and ameliorated microglia, but not astrocyte, reactivity. Furthermore, the elevated levels of amyloid plaques in the hippocampus were reduced by Boc2-treatment, presumably by an induction of amyloid degradation.
We suggest that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Additional studies are now needed to address the downstream effectors as well as the safety profile of Boc2. |
---|---|
AbstractList | Background An important hallmark of Alzheimer’s disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incomplete understanding of its relevance for AD. The chemotactic G-protein coupled formyl peptide receptor (FPR), which is known to modulate Aβ1-42 uptake and signal transduction, might be one candidate molecule regulating glia function in AD. Here, we investigate whether the modulation of FPR exerts beneficial effects in an AD preclinical model. Methods To address this question, APP/PS1 double-transgenic AD mice were treated for 20 weeks with either the pro-inflammatory FPR agonist fMLF, the FPR1/2 antagonist Boc2 or the anti-inflammatory FPR2 agonist Ac2-26. Spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining, gene expression studies, and flow cytometry analyses were performed to study neuronal loss, gliosis, and Aß-load in the hippocampus and cortex, respectively. Results FPR antagonism by Boc2-treatment significantly improved spatial memory performance, reduced neuronal pathology, induced the expression of homeostatic growth factors, and ameliorated microglia, but not astrocyte, reactivity. Furthermore, the elevated levels of amyloid plaques in the hippocampus were reduced by Boc2-treatment, presumably by an induction of amyloid degradation. Conclusions We suggest that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Additional studies are now needed to address the downstream effectors as well as the safety profile of Boc2. An important hallmark of Alzheimer's disease (AD) is the increase of A[beta]1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incomplete understanding of its relevance for AD. The chemotactic G-protein coupled formyl peptide receptor (FPR), which is known to modulate A[beta]1-42 uptake and signal transduction, might be one candidate molecule regulating glia function in AD. Here, we investigate whether the modulation of FPR exerts beneficial effects in an AD preclinical model. To address this question, APP/PS1 double-transgenic AD mice were treated for 20 weeks with either the pro-inflammatory FPR agonist fMLF, the FPR1/2 antagonist Boc2 or the anti-inflammatory FPR2 agonist Ac2-26. Spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining, gene expression studies, and flow cytometry analyses were performed to study neuronal loss, gliosis, and Ass-load in the hippocampus and cortex, respectively. FPR antagonism by Boc2-treatment significantly improved spatial memory performance, reduced neuronal pathology, induced the expression of homeostatic growth factors, and ameliorated microglia, but not astrocyte, reactivity. Furthermore, the elevated levels of amyloid plaques in the hippocampus were reduced by Boc2-treatment, presumably by an induction of amyloid degradation. We suggest that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Additional studies are now needed to address the downstream effectors as well as the safety profile of Boc2. An important hallmark of Alzheimer's disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incomplete understanding of its relevance for AD. The chemotactic G-protein coupled formyl peptide receptor (FPR), which is known to modulate Aβ1-42 uptake and signal transduction, might be one candidate molecule regulating glia function in AD. Here, we investigate whether the modulation of FPR exerts beneficial effects in an AD preclinical model. To address this question, APP/PS1 double-transgenic AD mice were treated for 20 weeks with either the pro-inflammatory FPR agonist fMLF, the FPR1/2 antagonist Boc2 or the anti-inflammatory FPR2 agonist Ac2-26. Spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining, gene expression studies, and flow cytometry analyses were performed to study neuronal loss, gliosis, and Aß-load in the hippocampus and cortex, respectively. FPR antagonism by Boc2-treatment significantly improved spatial memory performance, reduced neuronal pathology, induced the expression of homeostatic growth factors, and ameliorated microglia, but not astrocyte, reactivity. Furthermore, the elevated levels of amyloid plaques in the hippocampus were reduced by Boc2-treatment, presumably by an induction of amyloid degradation. We suggest that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Additional studies are now needed to address the downstream effectors as well as the safety profile of Boc2. Abstract Background An important hallmark of Alzheimer’s disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incomplete understanding of its relevance for AD. The chemotactic G-protein coupled formyl peptide receptor (FPR), which is known to modulate Aβ1-42 uptake and signal transduction, might be one candidate molecule regulating glia function in AD. Here, we investigate whether the modulation of FPR exerts beneficial effects in an AD preclinical model. Methods To address this question, APP/PS1 double-transgenic AD mice were treated for 20 weeks with either the pro-inflammatory FPR agonist fMLF, the FPR1/2 antagonist Boc2 or the anti-inflammatory FPR2 agonist Ac2-26. Spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining, gene expression studies, and flow cytometry analyses were performed to study neuronal loss, gliosis, and Aß-load in the hippocampus and cortex, respectively. Results FPR antagonism by Boc2-treatment significantly improved spatial memory performance, reduced neuronal pathology, induced the expression of homeostatic growth factors, and ameliorated microglia, but not astrocyte, reactivity. Furthermore, the elevated levels of amyloid plaques in the hippocampus were reduced by Boc2-treatment, presumably by an induction of amyloid degradation. Conclusions We suggest that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Additional studies are now needed to address the downstream effectors as well as the safety profile of Boc2. Background An important hallmark of Alzheimer's disease (AD) is the increase of A[beta]1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incomplete understanding of its relevance for AD. The chemotactic G-protein coupled formyl peptide receptor (FPR), which is known to modulate A[beta]1-42 uptake and signal transduction, might be one candidate molecule regulating glia function in AD. Here, we investigate whether the modulation of FPR exerts beneficial effects in an AD preclinical model. Methods To address this question, APP/PS1 double-transgenic AD mice were treated for 20 weeks with either the pro-inflammatory FPR agonist fMLF, the FPR1/2 antagonist Boc2 or the anti-inflammatory FPR2 agonist Ac2-26. Spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining, gene expression studies, and flow cytometry analyses were performed to study neuronal loss, gliosis, and Ass-load in the hippocampus and cortex, respectively. Results FPR antagonism by Boc2-treatment significantly improved spatial memory performance, reduced neuronal pathology, induced the expression of homeostatic growth factors, and ameliorated microglia, but not astrocyte, reactivity. Furthermore, the elevated levels of amyloid plaques in the hippocampus were reduced by Boc2-treatment, presumably by an induction of amyloid degradation. Conclusions We suggest that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Additional studies are now needed to address the downstream effectors as well as the safety profile of Boc2. Keywords: Alzheimer disease, Amyloid beta, Formyl peptide receptor, Glia cell, Microglia, Innate immunity, Annexin A1 Abstract Background An important hallmark of Alzheimer’s disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and neurodegeneration. The modulation of glia cell function represents an attractive therapeutic strategy, but is currently limited by an incomplete understanding of its relevance for AD. The chemotactic G-protein coupled formyl peptide receptor (FPR), which is known to modulate Aβ1-42 uptake and signal transduction, might be one candidate molecule regulating glia function in AD. Here, we investigate whether the modulation of FPR exerts beneficial effects in an AD preclinical model. Methods To address this question, APP/PS1 double-transgenic AD mice were treated for 20 weeks with either the pro-inflammatory FPR agonist fMLF, the FPR1/2 antagonist Boc2 or the anti-inflammatory FPR2 agonist Ac2-26. Spatial learning and memory were evaluated using a Morris water maze test. Immunohistological staining, gene expression studies, and flow cytometry analyses were performed to study neuronal loss, gliosis, and Aß-load in the hippocampus and cortex, respectively. Results FPR antagonism by Boc2-treatment significantly improved spatial memory performance, reduced neuronal pathology, induced the expression of homeostatic growth factors, and ameliorated microglia, but not astrocyte, reactivity. Furthermore, the elevated levels of amyloid plaques in the hippocampus were reduced by Boc2-treatment, presumably by an induction of amyloid degradation. Conclusions We suggest that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD. Additional studies are now needed to address the downstream effectors as well as the safety profile of Boc2. |
ArticleNumber | 131 |
Audience | Academic |
Author | Zhan, Jiangshan Samer, Sebastian Brandt, Elisa Schröder, Nicole Kipp, Markus Tauber, Simone C Kipp, Eugenia Pufe, Thomas Schaffrath, Anja Welter, Josua A Putzka, Tim Griep, Angelika Ziegler, Patrick Heneka, Michael T Kaddatz, Hannes Brandenburg, Lars-Ove |
Author_xml | – sequence: 1 givenname: Nicole surname: Schröder fullname: Schröder, Nicole organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 2 givenname: Anja surname: Schaffrath fullname: Schaffrath, Anja organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 3 givenname: Josua A surname: Welter fullname: Welter, Josua A organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 4 givenname: Tim surname: Putzka fullname: Putzka, Tim organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 5 givenname: Angelika surname: Griep fullname: Griep, Angelika organization: Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany – sequence: 6 givenname: Patrick surname: Ziegler fullname: Ziegler, Patrick organization: Institute for Occupational and Social Medicine, RWTH Aachen University, Aachen, Germany – sequence: 7 givenname: Elisa surname: Brandt fullname: Brandt, Elisa organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 8 givenname: Sebastian surname: Samer fullname: Samer, Sebastian organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 9 givenname: Michael T surname: Heneka fullname: Heneka, Michael T organization: German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany – sequence: 10 givenname: Hannes surname: Kaddatz fullname: Kaddatz, Hannes organization: Institute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, D-18057, Rostock, Germany – sequence: 11 givenname: Jiangshan surname: Zhan fullname: Zhan, Jiangshan organization: Institute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, D-18057, Rostock, Germany – sequence: 12 givenname: Eugenia surname: Kipp fullname: Kipp, Eugenia organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 13 givenname: Thomas surname: Pufe fullname: Pufe, Thomas organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany – sequence: 14 givenname: Simone C surname: Tauber fullname: Tauber, Simone C organization: Department of Neurology, RWTH University Hospital Aachen, Aachen, Germany – sequence: 15 givenname: Markus surname: Kipp fullname: Kipp, Markus organization: Institute of Anatomy, Rostock University Medical Center, Gertrudenstrasse 9, D-18057, Rostock, Germany – sequence: 16 givenname: Lars-Ove surname: Brandenburg fullname: Brandenburg, Lars-Ove email: Lars-Ove.Brandenburg@med.uni-rostock.de, Lars-Ove.Brandenburg@med.uni-rostock.de organization: Department of Anatomy and Cell Biology, RWTH Aachen University, Aachen, Germany. Lars-Ove.Brandenburg@med.uni-rostock.de |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32331524$$D View this record in MEDLINE/PubMed |
BookMark | eNptkt9rHCEQx6WkNMm1_0AfykKfN9HRdfWlcIT-OAj0pX0WV2fvPHbXq-4Fkr--Xi5NclAEHcaZD9_R7yU5m-KEhHxk9IoxJa8zA92KmgKtKVNM1vCGXLBWQA1Ui7NX8Tm5zHlLKYdGwjtyzoFz1oC4IHY1bUIX5hCnKvZVH9N4P1Q73M3BY5XQlSimXIVxl-Id5mreYBX3s4sjVmGqbDXGfcayexwOhOXwsMEwYqp8yGgzvidveztk_PB0Lsjvb19_3fyob39-X90sb2vXSD7XAhTT4KyCttFcUt_prmkbz3sHaBVvgXsN2gJIpgR14DUTQvau063XEviCrI5cH-3W7FIYbbo30QbzmIhpbWyagxvQdEIgMG6F0CgaRi2VTqDSnVIUZNcU1pcja7fvRvQOpznZ4QR6ejOFjVnHO9OWf2jKOy_I5ydAin_2mGezjfs0lfkNCCq4UprCS9XaFlVh6mOBuTFkZ5YSWi411wcxV_-pKsvjGFyxRB9K_qQBjg0uxZwT9s_CGTUH55ijc0xxjnl0jjlo-fR65OeWf1bhfwGwrr53 |
CitedBy_id | crossref_primary_10_1016_j_phrs_2024_107125 crossref_primary_10_1016_j_isci_2023_108153 crossref_primary_10_1186_s12974_023_02853_3 crossref_primary_10_4103_1673_5374_374013 crossref_primary_10_3390_life12122009 crossref_primary_10_3390_cells11213421 crossref_primary_10_3390_cells10102763 crossref_primary_10_1016_j_immuni_2024_03_010 crossref_primary_10_1016_j_toxicon_2022_106986 crossref_primary_10_1111_febs_15861 crossref_primary_10_1113_EP088953 crossref_primary_10_1515_hsz_2021_0258 crossref_primary_10_3389_fphar_2021_678611 crossref_primary_10_3389_fncel_2022_843790 crossref_primary_10_1016_j_jphs_2021_10_001 crossref_primary_10_3390_ijms22073706 crossref_primary_10_2174_1567205019666220805120303 crossref_primary_10_3390_molecules27154836 crossref_primary_10_1016_j_neulet_2021_136114 crossref_primary_10_3390_nu13051418 crossref_primary_10_1007_s12035_021_02543_2 crossref_primary_10_1016_j_neurobiolaging_2021_05_014 crossref_primary_10_3390_ijms22073439 crossref_primary_10_1016_j_bcp_2023_115524 crossref_primary_10_2174_0113892037275221240327042353 crossref_primary_10_1021_acschemneuro_3c00525 crossref_primary_10_1016_j_jbc_2022_102642 crossref_primary_10_3390_pharmaceutics15020352 |
Cites_doi | 10.1371/journal.pone.0060790 10.1172/JCI90606 10.1098/rsob.170228 10.3389/fphar.2019.00269 10.1007/s00401-016-1570-0 10.1111/j.1471-4159.2006.04351.x 10.1096/fj.10-159913 10.3233/JAD-2001-3111 10.1038/s41467-017-01943-0 10.1016/j.neuroscience.2008.07.042 10.1016/j.redox.2017.04.024 10.3390/ijms14047193 10.1038/nature11729 10.1186/s12974-019-1414-7 10.4103/1673-5374.205084 10.1186/s12974-019-1417-4 10.1182/blood-2005-08-3099 10.1186/1742-2094-8-11 10.1007/s00401-013-1182-x 10.1016/j.peptides.2010.11.019 10.1016/j.neuroscience.2018.05.002 10.15252/emmm.201606210 10.1186/s13024-016-0119-y 10.1038/382685a0 10.3389/fphar.2018.01015 10.1038/382716a0 10.1096/fj.12-205971 10.3233/JAD-180823 10.1111/j.1471-4159.2010.06637.x 10.1093/brain/awl249 10.1146/annurev.immunol.021908.132528 10.1186/s12974-016-0692-6 10.1096/fj.01-0251com 10.1016/j.nbd.2012.04.014 10.1016/S0197-4580(00)00092-0 10.1002/eji.201646551 10.1016/S0021-9258(18)91029-X 10.1074/jbc.M611050200 10.1007/s10753-007-9040-4 10.1016/j.tins.2017.04.002 10.3390/ijms20020257 10.1016/j.cell.2013.11.030 10.1172/JCI115105 10.3233/JAD-2004-6604 10.4049/jimmunol.1202030 10.1186/1750-1326-7-55 10.1189/jlb.3MR0416-204R 10.1038/nrmicro.2016.178 10.1172/JCI58644 10.1016/S1471-4906(02)02316-5 10.1007/s12031-017-0924-y 10.1038/bjp.2008.166 10.1111/j.1471-4159.2010.06783.x 10.1016/j.it.2016.06.006 10.1016/0016-5085(89)91410-8 10.1096/fj.201902172R 10.1159/000351436 10.1038/nrn3253 10.1523/JNEUROSCI.21-02-j0003.2001 10.1038/nrn3880 10.3390/molecules22030455 10.3233/JAD-2011-111778 10.1148/radiol.2016152244 10.1523/JNEUROSCI.0616-08.2008 10.1038/nrneurol.2017.188 10.1016/j.neurobiolaging.2008.07.022 10.2174/156720511794604543 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T5 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 5PM DOA |
DOI | 10.1186/s12974-020-01816-2 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Immunology Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts Immunology Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1742-2094 |
EndPage | 15 |
ExternalDocumentID | oai_doaj_org_article_b44e213a449e4510a06c4e89b88026b5 A627369395 10_1186_s12974_020_01816_2 32331524 |
Genre | Journal Article |
GeographicLocations | Germany |
GeographicLocations_xml | – name: Germany |
GrantInformation_xml | – fundername: Alzheimer Forschungsinitiative grantid: #13809 – fundername: Deutsche Forschungsgemeinschaft grantid: BR 3666/6-1 – fundername: ; grantid: BR 3666/6-1 – fundername: ; – fundername: ; grantid: #13809 |
GroupedDBID | --- -A0 0R~ 29L 2WC 3V. 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX CITATION ABVAZ AFGXO AFNRJ 7T5 7TK 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 5PM |
ID | FETCH-LOGICAL-c563t-428192ca82759360db9b575d3fc2ea83723d929a2261840c2d91446fcb97d9623 |
IEDL.DBID | RPM |
ISSN | 1742-2094 |
IngestDate | Tue Oct 22 15:14:20 EDT 2024 Tue Sep 17 20:55:33 EDT 2024 Thu Oct 10 20:39:24 EDT 2024 Thu Feb 22 23:56:07 EST 2024 Fri Feb 02 04:14:17 EST 2024 Thu Sep 12 19:41:42 EDT 2024 Sat Sep 28 08:23:56 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Amyloid beta Annexin A1 Alzheimer disease Formyl peptide receptor Innate immunity Glia cell Microglia |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c563t-428192ca82759360db9b575d3fc2ea83723d929a2261840c2d91446fcb97d9623 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181500/ |
PMID | 32331524 |
PQID | 2404388902 |
PQPubID | 55345 |
PageCount | 15 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b44e213a449e4510a06c4e89b88026b5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7181500 proquest_journals_2404388902 gale_infotracmisc_A627369395 gale_infotracacademiconefile_A627369395 crossref_primary_10_1186_s12974_020_01816_2 pubmed_primary_32331524 |
PublicationCentury | 2000 |
PublicationDate | 2020-04-24 |
PublicationDateYYYYMMDD | 2020-04-24 |
PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of neuroinflammation |
PublicationTitleAlternate | J Neuroinflammation |
PublicationYear | 2020 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | TB Sampaio (1816_CR43) 2017; 12 SD Yan (1816_CR12) 1996; 382 WA Marasco (1816_CR17) 1984; 259 CN Parkhurst (1816_CR63) 2013; 155 C Venegas (1816_CR8) 2017; 101 D Lorton (1816_CR50) 2000; 21 A Montagne (1816_CR54) 2016; 131 Y Le (1816_CR25) 2001; 21 M Moon (1816_CR39) 2012; 29 P Maderna (1816_CR60) 2010; 24 HD Perez (1816_CR20) 1991; 87 CS Janota (1816_CR58) 1620; 2015 I Galvao (1816_CR22) 2017; 47 M Coureuil (1816_CR59) 2017; 15 LO Brandenburg (1816_CR13) 2008; 156 LO Brandenburg (1816_CR14) 2010; 113 AL Stenfeldt (1816_CR23) 2007; 30 FN Gavins (1816_CR30) 2012; 26 H Sarlus (1816_CR7) 2017; 127 1816_CR26 MD Sweeney (1816_CR56) 2018; 14 CX Qin (1816_CR48) 2019; 10 DJ Selkoe (1816_CR67) 2016; 8 SF Kazim (1816_CR64) 2016; 11 DJ Selkoe (1816_CR1) 2001; 3 H Zhu (1816_CR38) 2017; 8 RM Ransohoff (1816_CR65) 2012; 122 PA Anton (1816_CR19) 1989; 97 RM Ransohoff (1816_CR6) 2009; 27 SM Rocha (1816_CR44) 2012; 47 C Li (1816_CR3) 2011; 8 E Colombo (1816_CR66) 2016; 37 A Bolander (1816_CR34) 2014; 13 H Zhang (1816_CR51) 2019; 67 S Prokop (1816_CR69) 2013; 126 HM Peshavariya (1816_CR61) 2013; 8 AD Gimenes (1816_CR49) 2019; 16 HJ van de Haar (1816_CR55) 2016; 281 Y Le (1816_CR15) 2002; 23 JZ Lacerda (1816_CR52) 2018; 9 M Ries (1816_CR70) 2016; 13 AP Girol (1816_CR29) 2013; 190 A Slowik (1816_CR27) 2012; 7 A Fragoulis (1816_CR32) 2017; 12 KC Ahn (1816_CR57) 2018; 385 FL Heppner (1816_CR2) 2015; 16 B Becker (1816_CR35) 2018; 55 DZ Christensen (1816_CR40) 2010; 31 HQ He (1816_CR16) 2017; 22 K Bihler (1816_CR33) 2017; 62 K Tahara (1816_CR9) 2006; 129 SS Ayoub (1816_CR53) 2008; 154 M Colucci (1816_CR18) 2011; 32 T Heurtaux (1816_CR24) 2010; 114 S Forner (1816_CR37) 2017; 40 GR Frost (1816_CR4) 2017; 7 BJ Braun (1816_CR46) 2011; 8 SD Skaper (1816_CR41) 1727; 2018 G Mudo (1816_CR68) 2019; 16 SE Hickman (1816_CR71) 2008; 28 J El Khoury (1816_CR10) 1996; 382 TKS Ng (1816_CR62) 2019; 20 LO Brandenburg (1816_CR45) 2007; 101 RP Hayhoe (1816_CR21) 2006; 107 ML Kashon (1816_CR5) 2004; 6 MG Machado (1816_CR31) 2020; 34 JL Jankowsky (1816_CR28) 2007; 282 AW Harrington (1816_CR42) 2013; 14 F Cattaneo (1816_CR47) 2013; 14 MT Heneka (1816_CR36) 2013; 493 GE Landreth (1816_CR11) 2009; 336 |
References_xml | – volume: 336 start-page: 137 year: 2009 ident: 1816_CR11 publication-title: Curr Top Microbiol Immunol. contributor: fullname: GE Landreth – volume: 55 start-page: 4240 issue: 5 year: 2018 ident: 1816_CR35 publication-title: Molecular neurobiology. contributor: fullname: B Becker – volume: 8 issue: 4 year: 2013 ident: 1816_CR61 publication-title: PLoS One. doi: 10.1371/journal.pone.0060790 contributor: fullname: HM Peshavariya – volume: 127 start-page: 3240 issue: 9 year: 2017 ident: 1816_CR7 publication-title: J Clin Invest. doi: 10.1172/JCI90606 contributor: fullname: H Sarlus – volume: 7 start-page: 170228 issue: 12 year: 2017 ident: 1816_CR4 publication-title: Open biology doi: 10.1098/rsob.170228 contributor: fullname: GR Frost – volume: 10 start-page: 269 year: 2019 ident: 1816_CR48 publication-title: Front Pharmacol. doi: 10.3389/fphar.2019.00269 contributor: fullname: CX Qin – volume: 131 start-page: 687 issue: 5 year: 2016 ident: 1816_CR54 publication-title: Acta neuropathologica. doi: 10.1007/s00401-016-1570-0 contributor: fullname: A Montagne – volume: 101 start-page: 718 issue: 3 year: 2007 ident: 1816_CR45 publication-title: J Neurochem. doi: 10.1111/j.1471-4159.2006.04351.x contributor: fullname: LO Brandenburg – volume: 24 start-page: 4240 issue: 11 year: 2010 ident: 1816_CR60 publication-title: FASEB journal : official publication of the Federation of American Societies for Experimental Biology. doi: 10.1096/fj.10-159913 contributor: fullname: P Maderna – volume: 3 start-page: 75 issue: 1 year: 2001 ident: 1816_CR1 publication-title: JAD. doi: 10.3233/JAD-2001-3111 contributor: fullname: DJ Selkoe – volume: 8 start-page: 1676 issue: 1 year: 2017 ident: 1816_CR38 publication-title: Nat Commun. doi: 10.1038/s41467-017-01943-0 contributor: fullname: H Zhu – volume: 156 start-page: 266 issue: 2 year: 2008 ident: 1816_CR13 publication-title: Neuroscience. doi: 10.1016/j.neuroscience.2008.07.042 contributor: fullname: LO Brandenburg – volume: 12 start-page: 843 year: 2017 ident: 1816_CR32 publication-title: Redox Biol. doi: 10.1016/j.redox.2017.04.024 contributor: fullname: A Fragoulis – volume: 14 start-page: 7193 issue: 4 year: 2013 ident: 1816_CR47 publication-title: Int J Mol Sci. doi: 10.3390/ijms14047193 contributor: fullname: F Cattaneo – volume: 493 start-page: 674 issue: 7434 year: 2013 ident: 1816_CR36 publication-title: Nature. doi: 10.1038/nature11729 contributor: fullname: MT Heneka – volume: 16 start-page: 32 issue: 1 year: 2019 ident: 1816_CR49 publication-title: Journal of neuroinflammation. doi: 10.1186/s12974-019-1414-7 contributor: fullname: AD Gimenes – volume: 12 start-page: 549 issue: 4 year: 2017 ident: 1816_CR43 publication-title: Neural Regen Res. doi: 10.4103/1673-5374.205084 contributor: fullname: TB Sampaio – volume: 16 start-page: 44 issue: 1 year: 2019 ident: 1816_CR68 publication-title: J Neuroinflammation. doi: 10.1186/s12974-019-1417-4 contributor: fullname: G Mudo – volume: 107 start-page: 2123 issue: 5 year: 2006 ident: 1816_CR21 publication-title: Blood. doi: 10.1182/blood-2005-08-3099 contributor: fullname: RP Hayhoe – volume: 8 start-page: 11 issue: 1 year: 2011 ident: 1816_CR46 publication-title: J Neuroinflammation. doi: 10.1186/1742-2094-8-11 contributor: fullname: BJ Braun – volume: 126 start-page: 461 issue: 4 year: 2013 ident: 1816_CR69 publication-title: Acta Neuropathol. doi: 10.1007/s00401-013-1182-x contributor: fullname: S Prokop – volume: 32 start-page: 266 issue: 2 year: 2011 ident: 1816_CR18 publication-title: Peptides. doi: 10.1016/j.peptides.2010.11.019 contributor: fullname: M Colucci – volume: 385 start-page: 246 year: 2018 ident: 1816_CR57 publication-title: Neuroscience. doi: 10.1016/j.neuroscience.2018.05.002 contributor: fullname: KC Ahn – volume: 8 start-page: 595 issue: 6 year: 2016 ident: 1816_CR67 publication-title: EMBO Mol Med. doi: 10.15252/emmm.201606210 contributor: fullname: DJ Selkoe – volume: 11 start-page: 50 issue: 1 year: 2016 ident: 1816_CR64 publication-title: Mol Neurodegener. doi: 10.1186/s13024-016-0119-y contributor: fullname: SF Kazim – volume: 382 start-page: 685 issue: 6593 year: 1996 ident: 1816_CR12 publication-title: Nature. doi: 10.1038/382685a0 contributor: fullname: SD Yan – volume: 9 start-page: 1015 year: 2018 ident: 1816_CR52 publication-title: Front Pharmacol. doi: 10.3389/fphar.2018.01015 contributor: fullname: JZ Lacerda – volume: 382 start-page: 716 issue: 6593 year: 1996 ident: 1816_CR10 publication-title: Nature. doi: 10.1038/382716a0 contributor: fullname: J El Khoury – volume: 26 start-page: 4977 issue: 12 year: 2012 ident: 1816_CR30 publication-title: Faseb j. doi: 10.1096/fj.12-205971 contributor: fullname: FN Gavins – volume: 67 start-page: 169 issue: 1 year: 2019 ident: 1816_CR51 publication-title: Journal of Alzheimer’s disease : JAD. doi: 10.3233/JAD-180823 contributor: fullname: H Zhang – volume: 113 start-page: 749 issue: 3 year: 2010 ident: 1816_CR14 publication-title: J Neurochem. doi: 10.1111/j.1471-4159.2010.06637.x contributor: fullname: LO Brandenburg – volume: 129 start-page: 3006 issue: Pt 11 year: 2006 ident: 1816_CR9 publication-title: Brain. doi: 10.1093/brain/awl249 contributor: fullname: K Tahara – volume: 27 start-page: 119 year: 2009 ident: 1816_CR6 publication-title: Annu Rev Immunol. doi: 10.1146/annurev.immunol.021908.132528 contributor: fullname: RM Ransohoff – volume: 13 start-page: 234 issue: 1 year: 2016 ident: 1816_CR70 publication-title: J Neuroinflammation. doi: 10.1186/s12974-016-0692-6 contributor: fullname: M Ries – ident: 1816_CR26 doi: 10.1096/fj.01-0251com – volume: 47 start-page: 407 issue: 3 year: 2012 ident: 1816_CR44 publication-title: Neurobiology of disease. doi: 10.1016/j.nbd.2012.04.014 contributor: fullname: SM Rocha – volume: 21 start-page: 463 issue: 3 year: 2000 ident: 1816_CR50 publication-title: Neurobiology of aging. doi: 10.1016/S0197-4580(00)00092-0 contributor: fullname: D Lorton – volume: 47 start-page: 585 issue: 3 year: 2017 ident: 1816_CR22 publication-title: European journal of immunology. doi: 10.1002/eji.201646551 contributor: fullname: I Galvao – volume: 259 start-page: 5430 issue: 9 year: 1984 ident: 1816_CR17 publication-title: J Biol Chem. doi: 10.1016/S0021-9258(18)91029-X contributor: fullname: WA Marasco – volume: 282 start-page: 22707 issue: 31 year: 2007 ident: 1816_CR28 publication-title: The Journal of biological chemistry. doi: 10.1074/jbc.M611050200 contributor: fullname: JL Jankowsky – volume: 30 start-page: 224 issue: 6 year: 2007 ident: 1816_CR23 publication-title: Inflammation. doi: 10.1007/s10753-007-9040-4 contributor: fullname: AL Stenfeldt – volume: 40 start-page: 347 issue: 6 year: 2017 ident: 1816_CR37 publication-title: Trends in neurosciences. doi: 10.1016/j.tins.2017.04.002 contributor: fullname: S Forner – volume: 20 start-page: 257 issue: 2 year: 2019 ident: 1816_CR62 publication-title: Int J Mol Sci doi: 10.3390/ijms20020257 contributor: fullname: TKS Ng – volume: 155 start-page: 1596 issue: 7 year: 2013 ident: 1816_CR63 publication-title: Cell. doi: 10.1016/j.cell.2013.11.030 contributor: fullname: CN Parkhurst – volume: 87 start-page: 971 issue: 3 year: 1991 ident: 1816_CR20 publication-title: The Journal of clinical investigation. doi: 10.1172/JCI115105 contributor: fullname: HD Perez – volume: 2018 start-page: 1 year: 1727 ident: 1816_CR41 publication-title: Methods Mol Biol. contributor: fullname: SD Skaper – volume: 6 start-page: 595 issue: 6 year: 2004 ident: 1816_CR5 publication-title: Journal of Alzheimer’s disease : JAD. doi: 10.3233/JAD-2004-6604 contributor: fullname: ML Kashon – volume: 190 start-page: 5689 issue: 11 year: 2013 ident: 1816_CR29 publication-title: J Immunol. doi: 10.4049/jimmunol.1202030 contributor: fullname: AP Girol – volume: 7 start-page: 55 issue: 1 year: 2012 ident: 1816_CR27 publication-title: Mol Neurodegener. doi: 10.1186/1750-1326-7-55 contributor: fullname: A Slowik – volume: 101 start-page: 87 issue: 1 year: 2017 ident: 1816_CR8 publication-title: J Leukoc Biol. doi: 10.1189/jlb.3MR0416-204R contributor: fullname: C Venegas – volume: 15 start-page: 149 issue: 3 year: 2017 ident: 1816_CR59 publication-title: Nature reviews Microbiology. doi: 10.1038/nrmicro.2016.178 contributor: fullname: M Coureuil – volume: 122 start-page: 1164 issue: 4 year: 2012 ident: 1816_CR65 publication-title: J Clin Invest. doi: 10.1172/JCI58644 contributor: fullname: RM Ransohoff – volume: 23 start-page: 541 issue: 11 year: 2002 ident: 1816_CR15 publication-title: Trends in immunology. doi: 10.1016/S1471-4906(02)02316-5 contributor: fullname: Y Le – volume: 62 start-page: 232 issue: 2 year: 2017 ident: 1816_CR33 publication-title: Journal of molecular neuroscience : MN. doi: 10.1007/s12031-017-0924-y contributor: fullname: K Bihler – volume: 154 start-page: 1135 issue: 5 year: 2008 ident: 1816_CR53 publication-title: Br J Pharmacol. doi: 10.1038/bjp.2008.166 contributor: fullname: SS Ayoub – volume: 114 start-page: 576 issue: 2 year: 2010 ident: 1816_CR24 publication-title: Journal of neurochemistry. doi: 10.1111/j.1471-4159.2010.06783.x contributor: fullname: T Heurtaux – volume: 37 start-page: 608 issue: 9 year: 2016 ident: 1816_CR66 publication-title: Trends Immunol. doi: 10.1016/j.it.2016.06.006 contributor: fullname: E Colombo – volume: 97 start-page: 20 issue: 1 year: 1989 ident: 1816_CR19 publication-title: Gastroenterology. doi: 10.1016/0016-5085(89)91410-8 contributor: fullname: PA Anton – volume: 34 start-page: 2749 issue: 2 year: 2020 ident: 1816_CR31 publication-title: FASEB J. doi: 10.1096/fj.201902172R contributor: fullname: MG Machado – volume: 13 start-page: 209 issue: 4 year: 2014 ident: 1816_CR34 publication-title: Neurodegener Dis. doi: 10.1159/000351436 contributor: fullname: A Bolander – volume: 14 start-page: 177 issue: 3 year: 2013 ident: 1816_CR42 publication-title: Nat Rev Neurosci. doi: 10.1038/nrn3253 contributor: fullname: AW Harrington – volume: 21 start-page: Rc123 issue: 2 year: 2001 ident: 1816_CR25 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.21-02-j0003.2001 contributor: fullname: Y Le – volume: 16 start-page: 358 issue: 6 year: 2015 ident: 1816_CR2 publication-title: Nat Rev Neurosci. doi: 10.1038/nrn3880 contributor: fullname: FL Heppner – volume: 22 start-page: 455 issue: 3 year: 2017 ident: 1816_CR16 publication-title: Molecules (Basel, Switzerland) doi: 10.3390/molecules22030455 contributor: fullname: HQ He – volume: 29 start-page: 615 issue: 3 year: 2012 ident: 1816_CR39 publication-title: Journal of Alzheimer’s disease : JAD. doi: 10.3233/JAD-2011-111778 contributor: fullname: M Moon – volume: 281 start-page: 527 issue: 2 year: 2016 ident: 1816_CR55 publication-title: Radiology. doi: 10.1148/radiol.2016152244 contributor: fullname: HJ van de Haar – volume: 28 start-page: 8354 issue: 33 year: 2008 ident: 1816_CR71 publication-title: J Neurosci. doi: 10.1523/JNEUROSCI.0616-08.2008 contributor: fullname: SE Hickman – volume: 2015 start-page: 153 year: 1620 ident: 1816_CR58 publication-title: Brain research. contributor: fullname: CS Janota – volume: 14 start-page: 133 issue: 3 year: 2018 ident: 1816_CR56 publication-title: Nature reviews Neurology. doi: 10.1038/nrneurol.2017.188 contributor: fullname: MD Sweeney – volume: 31 start-page: 1153 issue: 7 year: 2010 ident: 1816_CR40 publication-title: Neurobiology of aging. doi: 10.1016/j.neurobiolaging.2008.07.022 contributor: fullname: DZ Christensen – volume: 8 start-page: 67 issue: 1 year: 2011 ident: 1816_CR3 publication-title: Current Alzheimer research. doi: 10.2174/156720511794604543 contributor: fullname: C Li |
SSID | ssj0032562 |
Score | 2.4594069 |
Snippet | An important hallmark of Alzheimer's disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive gliosis and... Abstract Background An important hallmark of Alzheimer’s disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the... Background An important hallmark of Alzheimer's disease (AD) is the increase of A[beta]1-42 burden and its accumulation to senile plaques, leading the reactive... An important hallmark of Alzheimer's disease (AD) is the increase of A[beta]1-42 burden and its accumulation to senile plaques, leading the reactive gliosis... Background An important hallmark of Alzheimer’s disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the reactive... Abstract Background An important hallmark of Alzheimer’s disease (AD) is the increase of Aβ1-42 burden and its accumulation to senile plaques, leading the... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 131 |
SubjectTerms | Agonists Alzheimer disease Alzheimer Disease - metabolism Alzheimer Disease - pathology Alzheimer's disease Amyloid Amyloid beta Animals Brain - drug effects Brain - metabolism Brain - pathology Care and treatment Cell receptors Cognitive ability Disease Models, Animal Flow cytometry Formyl peptide receptor Formyl peptide receptors Gene expression Gene flow Glia cell Gliosis Growth factors Hippocampus Inflammation Innate immunity Maze Learning - drug effects Memory Mice Mice, Transgenic Microglia Mutation Neurodegeneration Neurodegenerative diseases Neuromodulation Neuronal-glial interactions Oligopeptides - pharmacology Pathogens Peptides Physiological aspects Presenilin 1 Proteins Receptors, Formyl Peptide - antagonists & inhibitors Rodents Senile plaques Signal transduction Software Spatial discrimination learning Spatial memory Transgenic animals Transgenic mice |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhh5BLaZu0dZsWHQo5BJHVw7J13JaEpNCeEshNSPKYNaTesLs5NL8-M7I3rOmhl96MJYw8D8030ugTY1-jbEtpVRIRFSyMkiAiVFGUOoGV0rYScpXvL3t1a37clXc7V31RTdhADzwI7jwaA0rqYIwDgwYUZjYZqF1Ew1M2DuylstwmU8McrDGQq-0RmdqerzGqVUZQqkQEVVaoSRjKbP1_z8k7QWlaMLkTgS5fs1cjdOTzYchv2B70b9nBz3Fz_IiF637RxVyCxZctJzT6554_UNlKAxxnNnxarta8y-sIsOaI_fjycYM2B7zreeC0DAA8X45DX5jfPy2g-w0rPm7jHLPby4ub71divEFBpNLqDcqe-M5SqFVFN_fNmugi4rNGt0lBwNxU6QbxUUAMRpleUo2j_LBN0VWNQ2T0ju33yx4-MD6zLXm41Mk6hGAhYuKpIMXGVI2uIRbsbCtQ_zAQZficYNTWD-L3KH6fxe9Vwb6RzF96Esl1foGq96Pq_b9UX7BT0pgnV0S1pDCeKMABE6mVn1vEZtZphz1PJj3RhdK0eatzP7rw2iviHappG7Zg7wf1vwxXK60R-JiCVRPDmPzPtKXvFpm8G7EAYvDZx_8hgE_sUGWbNkKZE7a_WT3CZ8RIm_glu8MzEmQLOw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9UwDI9gkxAXxDeFgXJA4oCivSZp2p7QG9o0kJgQYtJuUZK6vEpb-3h9O8Bfj52XjlVI3Kom6ocd2z_Hjs3YW5-3RW5kEB4ZLLTMQXgovShUAJPnps0hZvmemdNz_fmiuEgbbmNKq5x0YlTUzRBoj_xQUhmYiqJiH9Y_BXWNouhqaqFxl-3LXFOYdv_o-Ozrt0kXKzTocjoqU5nDEa1bqQW5TFSoygg5M0exav-_uvmWcZonTt6yRCcP2YMEIflyx_NH7A70j9m9LylI_oS5T_2q8zEViw8tJ1T665KvKX2lAY4aDq-Gzci7uJ8AI0cMyIfrLdIBeNdzx2k7AHhskkNPWF7-XkF3BRuewjlP2fnJ8fePpyJ1UhChMGqLPKC6Z8FVsqQOfovG1x5xWqPaIMGhjypVgzjJIRYjjy_IpiY_sQ2-LpsaEdIzttcPPbxgfGFakvRcBVMjFHMeHVAJwTe6bFQFPmPvJ4La9a5gho2ORmXsjvwWyW8j-a3M2BHR_GYmFbuON4bND5tkx3qtQebKaV2DRh3iFiZoqGqPukcaX2TsHXHMkkgiW4JLJwvwg6m4lV0axGimVjXOPJjNRFEK8-GJ5zaJ8mj_LryMPd-x_-ZzlVQKAZDOWDlbGLP_mY_03SoW8UZMgFh88fL_r3zF7su4WrWQ-oDtbTfX8BpR0Na_SUv9D93qBS8 priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaqIiEuiPIMbZEPSByQYWM7Tnyo0BZRFaRyYqXerNiZsJGWpGS3UsuvZ8abrBpRcYtiJ3Hm-Y0fM4y99WmdpUYG4ZHBQssUhIfci0wFMGlq6hTiLt_v5nyhv11ml3tsLHc0EHB9b2hH9aQW_erDze_bT6jwJ1HhC_NxjT4r14ICIUo_ZQSa5AdSK00Sf6F3qwoK3bscD87c-9zEOcUc_v9a6juuarqN8o5fOnvCHg-Aks-3EnDA9qB9yh5eDEvmz1j5tV02Pm7M4l3NCaPervgVbWapgKO9w6uuX_Mmzi7AmiMi5N31BiUReNPyktPkAPBYMofeMF_9WULzC3o-LO48Z4uzLz8-n4uhroIImVEb5AhlQQtlIXOq5zervPWI2ipVBwklRqxSVYiaSkRmFP8FWVmKGuvgbV5ZxEsv2H7btfCK8ZmpSe9TFYxFYFZ6DEclBF_pvFIF-IS9HwnqrrbpM1wMOwrjtuR3SH4Xye9kwk6J5ruelPo63uj6n27QJOe1BpmqUmsLGi1KOTNBQ2E9WiJpfJawd8QxRyKDbAnlcM4AB0yprtzcIGIzVlnseTTpiYoVps0jz90ol05SNqKCFmcT9nLL_t1wlVQK4ZBOWD4RjMn_TFvaZhlTeiNCQGQ-e_3_Tx6yRzJKqxZSH7H9TX8Nx4iJNv5NFPS_o5EG_g priority: 102 providerName: Scholars Portal |
Title | Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32331524 https://www.proquest.com/docview/2404388902 https://pubmed.ncbi.nlm.nih.gov/PMC7181500 https://doaj.org/article/b44e213a449e4510a06c4e89b88026b5 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9swFH-0HYxdxr7nrQs6DHYYbmJJlu1jWlq6QUoZK-QmJFleDIkdkvSw_fV7T7ZLzW67GGPLRvbvffye9PQE8NkmVZoo7mKLAMeSJz62PrNxKpxXSaKqxIcs3xt1fSe_L9PlEaTDWpiQtO9sfdasN2dNvQq5lduNmw55YtPbxQXaU-Qxs-kxHGdCDCF6Z34F-nA-rI7J1XSPDi2TMUVJVJtKxbR_jeBCoOOSI2cUavb_a5kfuaZx2uQjP3T1Ap73BJLNu46-hCPfvIKni36K_DWYb82qtiERi7UVI076e822lLxSeob2Dc_a3Z7VYTTB7xkyQNbeH1DyPKsbZhgNBngWtsihN8zXf1a-3vgd6ydz3sDd1eXPi-u430chdqkSB0SAqp45k_OM9u-blbawyNJKUTnuDUaoXJTIkgwyMYr3HC8LihIrZ4usLJAfvYWTpm38e2AzVZGeJ8KpAomYsRh-cu9sKbNS5N5G8HX4oXrblcvQIczIle6Q0IiEDkhoHsE5_fOHllTqOlxod790D7i2UnqeCCNl4SVaEDNTTvq8sGh5uLJpBF8IMU0KibA4068rwA5TaSs9V8jQVCEKbHk6aomK5Ma3B8x1r8h7zan6UE6TsRG86-B_6O4gRRFkI8EYfc_4Dkp0KOHdS_CH_37yIzzjQaZlzOUpnBx29_4T0qODnaBSLLMJPDm_vLn9MQmDDHhcyHwSFOUvMMwQ-w |
link.rule.ids | 230,315,733,786,790,870,891,2115,12083,21416,24346,27955,27956,31752,33777,43343,43838,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKwEXxJtAAR-QOCCrG9tx4hPaolZbaFcItVJvVuw43Ugl2W62h_LrmfE6pREStyix8pjxzHxjT74h5KNN6yxV3DELCmaSp55Zn1uWCedVmqo69aHKd6HmZ_LbeXYeF9z6WFY5-MTgqKvO4Rr5HkcamAJ3xb6srhh2jcLd1dhC4z7ZQcrNYkJ29g8WP34OvlhAQOfDrzKF2ushuuWSYcqERFWK8VE4Cqz9__rmO8FpXDh5JxIdPiGPI4Sks63On5J7vn1GHpzETfLnpDxql40NpVi0qymi0ptLusLylcpT8HBw1K172oT1BN9TwIC0u96AHDxtWlpSXA7wNDTJwTvMLn8vffPLr2ncznlBzg4PTr_OWeykwFymxAZ0gLxnrix4jh38ppXVFnBaJWrHfQk5KhcV4KQSsBhmfI5XGvPE2lmdVxoQ0ksyabvWvyZ0qmq09FQ4pQGKlRYSUO6drWReicLbhHweBGpWW8IMExKNQpmt-A2I3wTxG56QfZT57Ugkuw4nuvWFibZjrJSep6KUUnsJPqScKid9oS34Hq5slpBPqDGDJglqcWX8swBeGMmtzEwBRlNaaBi5OxoJpuTGlwedm2jKvfk78RLyaqv-29cVXAgAQDIh-WhijL5nfKVtloHEGzABYPHpm_8_8gN5OD89OTbHR4vvb8kjHmauZFzukslmfe3fASLa2Pdx2v8BX6cIJQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkSouvB-BAj4gcUDebGzHSY5LYdUCrXqgUsXFih2HjdhNVrvZA_31jJ2k2sCttyhxojjz-saefAPwXkdlHElmqEYBU8EiS7VNNI25sTKKZBlZX-V7Lk8uxder-Gqv1Zcv2je6mtTL1aSuFr62cr0y4VAnFl6cHaM_RRwzDddFGd6Fe2izLBkS9c4Jc4zkbPhHJpXhFsNaIqjLlRxDlaSuiw1nnGP4EqOQ5Jn7__fPewFqXDy5F43mD-HnMI-uCOX3ZNfqibn-h-LxVhN9BA96jEpm3ZDHcMfWT-DwrN-Ffwr5ab2otK_1Ik1JHOz9syRrVx9TWIIuFI-azZZUfsHCbgmCTNLsWlRuS6qa5MStN1jiu_C4J8yW1wtbreyG9PtFz-By_uXH8QntWzVQE0veopAdsZrJURCuReC00JlGIFjw0jCbYxLMeIFALEew51JKw4rMJaKl0VlSZAjBnsNB3dT2JZCpLJ0ribiRGWK9XGOGy6zRhUgKnlodwMdBWmrdMXIon8mkUnViVihm5cWsWACfnEBvRjo2bX-i2fxS_adWWgjLIp4LkVmBTiqfSiNsmml0bkzqOIAPTh2Us3mUucn7XxfwhR17lppJBIEy4xmOPBqNRFs148uDQqneV2wVcwRHqdvvDeBFp1s3rzuoaADJSOtG8xlfQV3yLOG97ry69Z3v4PDi81x9Pz3_9hruM287gjJxBAftZmffIBhr9Vtvdn8BbRExFw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+formyl+peptide+receptors+improves+the+outcome+in+a+mouse+model+of+Alzheimer+disease&rft.jtitle=Journal+of+neuroinflammation&rft.au=Schr%C3%B6der%2C+Nicole&rft.au=Schaffrath%2C+Anja&rft.au=Welter%2C+Josua+A&rft.au=Putzka%2C+Tim&rft.date=2020-04-24&rft.pub=BioMed+Central&rft.eissn=1742-2094&rft.volume=17&rft.spage=1&rft_id=info:doi/10.1186%2Fs12974-020-01816-2 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon |